Temazepam is an intermediate-acting benzodiazepine specifically indicated for insomnia. It has a half-life of 8-15 hours, making it suitable for sleep maintenance with relatively minimal next-day sedation. It is one of the most commonly prescribed benzodiazepines for sleep disorders and has a well-established safety and efficacy profile for short-term insomnia treatment.
Clinical Overview
Primary Clinical Applications
Temazepam is indicated for the short-term treatment of insomnia, particularly for patients with difficulty maintaining sleep throughout the night. Its intermediate duration of action provides effective sleep maintenance while minimizing next-day impairment, making it suitable for patients who need to be alert in the morning.
Mechanism and Clinical Benefits
Temazepam enhances GABA activity at benzodiazepine receptors, providing sedative and hypnotic effects. Its pharmacokinetic profile with an 8-15 hour half-life allows for sustained sleep throughout the night while being eliminated sufficiently by morning to reduce hangover effects.
Clinical Considerations
Like all benzodiazepines, temazepam carries risks of tolerance, dependence, and withdrawal syndrome. It should be used for the shortest duration possible (typically 7-10 days) and requires gradual tapering when discontinued. The medication can cause anterograde amnesia and complex sleep behaviors, requiring patient education about proper use and potential risks.
Key Clinical Points
Intermediate half-life suits sleep maintenance
Eight to fifteen hours covers the night without the multi-day accumulation of flurazepam or quazepam, which is why it remains the most widely prescribed benzodiazepine hypnotic.
Pregnancy Category X
Contraindicated in pregnancy. Also contraindicated in sleep apnoea syndrome, severe respiratory insufficiency, severe hepatic impairment, and myasthenia gravis.
Maximum 15 mg in older adults
Half the adult maximum, reflecting increased sensitivity and falls risk. Start at 7.5 mg in this group.
Anterograde amnesia and complex sleep behaviours
Memory loss for events after dosing, along with sleep-driving and sleep-eating, have been reported. Patients rarely volunteer these and should be asked directly.
Seven to ten days where possible
Dependence risk rises with duration and dose. Carries the class boxed warning for abuse, dependence, and respiratory depression with opioids.
Prescribing Information
Dosing & Administration
Insomnia – Adults:
- Usual dose: 15 mg at bedtime
- Range: 7.5-30 mg at bedtime
- Maximum: 30 mg at bedtime
Elderly or Debilitated:
- Initial: 7.5 mg at bedtime
- Range: 7.5-15 mg at bedtime
- Maximum: 15 mg at bedtime
Administration:
- Take immediately before bedtime
- Ensure 7-8 hours available for sleep
- May take with or without food
- Limit treatment duration to 7-10 days when possible
Indications
- Short-term treatment of insomnia
- Sleep maintenance difficulties
Contraindications
- Hypersensitivity to benzodiazepines
- Sleep apnea syndrome
- Severe respiratory insufficiency
- Severe hepatic insufficiency
- Myasthenia gravis
- Pregnancy (particularly first trimester)
Warnings & Precautions
- Boxed Warning: Risk of abuse, misuse, dependence; respiratory depression with opioids
- Complex sleep behaviors: Sleep-driving, sleep-eating reported
- Physical dependence: Risk increases with dose and duration
- Withdrawal syndrome: Taper gradually when discontinuing
- Anterograde amnesia: Memory impairment possible
- Falls risk: Particularly in elderly patients
- Respiratory depression: Enhanced with CNS depressants
Drug Interactions
- Opioids: Increased risk of respiratory depression and death
- CNS depressants: Enhanced sedation and respiratory depression
- Alcohol: Dangerous potentiation of effects
- CYP3A4 inhibitors: May increase temazepam levels
Adverse Reactions
Common (>5%):
- Drowsiness, headache, fatigue, nervousness
- Lethargy, confusion, euphoria
Serious:
- Respiratory depression, complex sleep behaviors
- Severe withdrawal syndrome, dependence
Special Populations
- Elderly: Increased sensitivity, maximum 15 mg daily
- Hepatic Impairment: Use caution, may require dose reduction
- Pregnancy: Category X – avoid in pregnancy
- Short-term use: Limit to 7-10 days to minimize dependence risk
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
